Elevance Health, Inc. — Form 8-K
Filed October 21, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Elevance Health reported Q3 2026 operating revenue of $50.4B (up 0.7% YoY), diluted EPS of $6.27, and adjusted diluted EPS of $6.99. The company raised full-year 2026 diluted EPS guidance to at least $22.00 (adjusted: at least $29.00) and operating cash flow guidance to at least $6.5B, citing improved operating performance. However, the filing discloses a $935M accrual for potential exposure related to historical Medicare Advantage risk adjustment data following a Feb 27, 2026 CMS notice—a material headwind to operating results that reduced nine-month operating gain by 25.7% YoY.
Why this rating
Guidance raise is positive but offset by $935M (~1.1% of market cap) Medicare compliance accrual. Medical membership declined 487K YoY; modest 0.7% revenue growth. Mixed signals warrant neutral stance.
See more from October 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.